Literature DB >> 33210422

Response to 'Is the case really a SMARCA4-deficient thoracic sarcoma?'

Kohichi Takada1, Shintaro Sugita2, Tadashi Hasegawa2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33210422      PMCID： PMC7779208          DOI： 10.1111/1759-7714.13751

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN： 1759-7706            Impact factor:   3.500


× No keyword cloud information.
  4 in total

1.  CORRIGENDUM.

Authors: 
Journal:  Thorac Cancer       Date:  2020-12       Impact factor: 3.500

2.  Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.

Authors:  Kei Kunimasa; Harumi Nakamura; Kazuko Sakai; Motohiro Tamiya; Madoka Kimura; Takako Inoue; Kazumi Nishino; Hanako Kuhara; Shin-Ichi Nakatsuka; Kazuto Nishio; Fumio Imamura; Toru Kumagai
Journal:  Lung Cancer       Date:  2019-04-08       Impact factor: 5.705

3.  Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.

Authors:  Kohichi Takada; Shintaro Sugita; Kazuyuki Murase; Tomoki Kikuchi; Ginji Oomori; Ryo Ito; Naotaka Hayasaka; Koji Miyanishi; Satoshi Iyama; Hiroshi Ikeda; Masayoshi Kobune; Makoto Emori; Junji Kato; Tadashi Hasegawa
Journal:  Thorac Cancer       Date:  2019-10-16       Impact factor: 3.500

4.  Is the case really a SMARCA4-deficient thoracic sarcoma?

Authors:  Kei Kunimasa
Journal:  Thorac Cancer       Date:  2020-10-19       Impact factor: 3.500
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.